{"id":"puva-8-mop-uva","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Erythema and phototoxic burn"},{"rate":"10-30","effect":"Pruritus"},{"rate":"5-15","effect":"Nausea"},{"rate":"1-5","effect":"Cataracts (with long-term use)"},{"rate":"variable with cumulative dose","effect":"Photoaging and skin atrophy"},{"rate":"dose-dependent","effect":"Increased risk of non-melanoma skin cancer"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"8-MOP is an oral psoralen that intercalates into DNA when activated by UVA light (320-400 nm), creating thymine dimers and generating reactive oxygen species that trigger apoptosis in cutaneous lymphocytes. This mechanism is particularly effective against malignant T cells in cutaneous lymphomas while also providing immunosuppressive effects that benefit inflammatory skin conditions. The combination of photochemical DNA damage and immune modulation makes PUVA effective for both neoplastic and inflammatory cutaneous disorders.","oneSentence":"PUVA therapy uses 8-methoxypsoralen (8-MOP) as a photosensitizing agent combined with UVA radiation to induce apoptosis in malignant T cells and suppress immune-mediated skin inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:27.939Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cutaneous T-cell lymphoma (mycosis fungoides)"},{"name":"Psoriasis"},{"name":"Vitiligo"},{"name":"Lichen planus"},{"name":"Polymorphous light eruption"}]},"trialDetails":[{"nctId":"NCT05718674","phase":"","title":"Photopheresis in GvHD After Hematopoietic Transplantation: Characteristics of the Procedure and of the Cell Product","status":"COMPLETED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-05-26","conditions":"Graft Vs Host Disease, Extracorporeal Photopheresis","enrollment":27},{"nctId":"NCT00179855","phase":"PHASE2, PHASE3","title":"Extracorporeal Photopheresis for Acute Graft Versus Host Disease","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2003-07","conditions":"Graft Versus Host Disease, Cancer, Stem Cell Transplantation","enrollment":10},{"nctId":"NCT05333367","phase":"NA","title":"MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-04-15","conditions":"Cutaneous T-Cell Lymphoma, Graft Vs Host Disease, Graft Rejection","enrollment":20},{"nctId":"NCT04792294","phase":"","title":"Multicenter Analysis of Efficacy and Outcomes of Extracorporeal Photopheresis as Treatment of Chronic Lung Allograft Dysfunction","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2005-01-01","conditions":"Lung Transplant Rejection","enrollment":800},{"nctId":"NCT00724061","phase":"NA","title":"Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-09","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT01686594","phase":"PHASE3","title":"PUVA Maintenance Therapy in Mycosis Fungoides","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2013-02","conditions":"Patch/Plaque Stage Mycosis Fungoides","enrollment":28},{"nctId":"NCT00056056","phase":"PHASE3","title":"Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2003-01","conditions":"Lymphoma","enrollment":93},{"nctId":"NCT02631993","phase":"","title":"Photochemotherapy and Graft-versus-leukemia in Acute-leukemia","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2014-10","conditions":"ALL, AML, Acute GVHD","enrollment":47},{"nctId":"NCT01559584","phase":"NA","title":"Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2012-03","conditions":"Alopecia Areata","enrollment":40},{"nctId":"NCT01402414","phase":"NA","title":"Narrow-band (NB)-UVB vs. Bath-PUVA and NB-UVB Plus Salt Water Baths in Atopic Dermatitis","status":"TERMINATED","sponsor":"Ruhr University of Bochum","startDate":"2011-04","conditions":"Atopic Dermatitis","enrollment":10},{"nctId":"NCT00811005","phase":"PHASE3","title":"Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2008-10","conditions":"Pustular Palmoplantar Psoriasis","enrollment":20},{"nctId":"NCT00533195","phase":"PHASE3","title":"Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT00630903","phase":"PHASE4","title":"PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides","status":"TERMINATED","sponsor":"Madrilenian Group of Cutaneous Lymphomas","startDate":"2000-01","conditions":"Cutaneous T-Cell Lymphoma (Mycosis Fungoides)","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PUVA (8-MOP + UVA)","genericName":"PUVA (8-MOP + UVA)","companyName":"Madrilenian Group of Cutaneous Lymphomas","companyId":"madrilenian-group-of-cutaneous-lymphomas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PUVA combines 8-methoxypsoralen (8-MOP), a photosensitizing agent, with UVA radiation to create DNA cross-links in rapidly dividing cells, inducing apoptosis in malignant lymphocytes. Used for Cutaneous T-cell lymphoma (mycosis fungoides), Cutaneous B-cell lymphoma, Severe psoriasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}